I期临床-话题@MedSci

#I期临床#

570篇内容 | 7038人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653041, encodeId=d695165304139, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, objectType=article, longId=195935, objectId=1c30195935d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c30195935d4, replyNumber=0, likeNumber=111, createdTime=2021-02-16, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c30195935d4, moduleTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c30195935d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653131, encodeId=a8541653131ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, objectType=article, longId=203849, objectId=7f4820384995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f4820384995, replyNumber=0, likeNumber=79, createdTime=2021-09-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f4820384995, moduleTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f4820384995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653075, encodeId=8b4b16530e53f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果, objectType=article, longId=199491, objectId=6d08199491a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d08199491a0, replyNumber=0, likeNumber=95, createdTime=2021-04-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d08199491a0, moduleTitle=NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d08199491a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653173, encodeId=577716531e3e9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, objectType=article, longId=209558, objectId=b719209558c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b719209558c2, replyNumber=0, likeNumber=83, createdTime=2021-06-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b719209558c2, moduleTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b719209558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653098, encodeId=1bfb165309850, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, objectType=article, longId=201506, objectId=3857201506d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3857201506d7, replyNumber=0, likeNumber=70, createdTime=2021-06-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3857201506d7, moduleTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3857201506d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653069, encodeId=bc5f165306944, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, objectType=article, longId=199161, objectId=739d19916169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739d19916169, replyNumber=0, likeNumber=53, createdTime=2020-12-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739d19916169, moduleTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=739d19916169)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653033, encodeId=c1a716530331a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, objectType=article, longId=194690, objectId=fbb4194690aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbb4194690aa, replyNumber=0, likeNumber=68, createdTime=2020-10-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbb4194690aa, moduleTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbb4194690aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653055, encodeId=bee7165305532, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, objectType=article, longId=197670, objectId=9e0019e6706c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0019e6706c, replyNumber=0, likeNumber=89, createdTime=2021-01-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0019e6706c, moduleTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0019e6706c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653102, encodeId=8cfe1653102ab, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床, objectType=article, longId=201817, objectId=ab3520181ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab3520181ee0, replyNumber=0, likeNumber=75, createdTime=2021-03-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab3520181ee0, moduleTitle=GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab3520181ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653174, encodeId=811b16531e4f1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, objectType=article, longId=209763, objectId=515e209e63ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=515e209e63ce, replyNumber=0, likeNumber=70, createdTime=2021-11-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=515e209e63ce, moduleTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=515e209e63ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653019, encodeId=4c3516530197a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果, objectType=article, longId=193524, objectId=6f49193524a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f49193524a1, replyNumber=0, likeNumber=50, createdTime=2020-11-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f49193524a1, moduleTitle=女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f49193524a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653135, encodeId=18011653135ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, objectType=article, longId=204591, objectId=0d4f2045916e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4f2045916e, replyNumber=0, likeNumber=83, createdTime=2021-07-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4f2045916e, moduleTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4f2045916e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653115, encodeId=723c165311514, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, objectType=article, longId=202718, objectId=5865202e1851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5865202e1851, replyNumber=0, likeNumber=67, createdTime=2021-01-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5865202e1851, moduleTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5865202e1851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653113, encodeId=3c631653113d4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, objectType=article, longId=202651, objectId=9ce020265159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ce020265159, replyNumber=0, likeNumber=80, createdTime=2021-04-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ce020265159, moduleTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ce020265159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653029, encodeId=b89a1653029b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=张伯礼：加快新冠病毒疫苗III期临床试验, objectType=article, longId=194542, objectId=0f3a194542ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3a194542ed, replyNumber=0, likeNumber=133, createdTime=2020-10-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3a194542ed, moduleTitle=张伯礼：加快新冠病毒疫苗III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3a194542ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653136, encodeId=735416531364c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, objectType=article, longId=204701, objectId=9ebf204e014c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ebf204e014c, replyNumber=0, likeNumber=43, createdTime=2021-10-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ebf204e014c, moduleTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ebf204e014c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653020, encodeId=8300165302048, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, objectType=article, longId=193525, objectId=9a4819352542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a4819352542, replyNumber=0, likeNumber=0, createdTime=2020-09-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a4819352542, moduleTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a4819352542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653017, encodeId=47e2165301e5f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, objectType=article, longId=193204, objectId=9f0e19320472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0e19320472, replyNumber=0, likeNumber=54, createdTime=2020-12-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0e19320472, moduleTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0e19320472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653169, encodeId=c36e1653169e6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, objectType=article, longId=208907, objectId=e5a320890ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a320890ef2, replyNumber=0, likeNumber=64, createdTime=2021-09-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a320890ef2, moduleTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5a320890ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653078, encodeId=f98016530e8a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JAMA：灭活全病毒Covid-19疫苗I-II期临床获得成功, objectType=article, longId=199946, objectId=6817199946dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6817199946dd, replyNumber=0, likeNumber=108, createdTime=2020-09-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6817199946dd, moduleTitle=JAMA：灭活全病毒Covid-19疫苗I-II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6817199946dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

heli0118 (审核中...)

前往app查看评论内容

#I期临床#

关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验

2021-02-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA批准AMZ002治疗婴儿癫痫病的III期临床试验

2021-09-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果

2021-04-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功

2021-06-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Xevinapant治疗头颈癌：步入大型III期临床试验

2021-06-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验

2020-12-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验

2020-10-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验

2021-01-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床

2021-03-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解

2021-11-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果

2020-11-06

zhaojie88 (审核中...)

前往app查看评论内容

#I期临床#

EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床

2021-07-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验

2021-01-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果

2021-04-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

张伯礼：加快新冠病毒疫苗III期临床试验

2020-10-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果

2021-10-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始

2020-09-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

瑞德西韦治疗重症住院COVID-19患者III期临床数据公开

2020-12-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点

2021-09-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JAMA：灭活全病毒Covid-19疫苗I-II期临床获得成功

2020-09-03

科室
- - 订阅+
  - 更多科室
工具
服务